Nutriband Inc. Advances AVERSA(TM) Fentanyl Abuse-Deterrent Patch with FDA Type C Meeting Scheduled

Nutriband Inc. (NASDAQ: NTRB), a leader in the development of prescription transdermal pharmaceutical products, has announced a pivotal milestone in the advancement of its AVERSA(TM) Fentanyl abuse-deterrent patch. The U.S. Food and Drug Administration (FDA) has scheduled a Type C Meeting for September 18, 2025, to review the Chemistry, Manufacturing, and Controls (CMC) plans for this innovative product. This meeting represents a critical step in the regulatory process, bringing Nutriband closer to offering a solution designed to mitigate the risks associated with fentanyl patches, including abuse, diversion, misuse, and accidental exposure.

Developed in collaboration with Kindeva, a company with an FDA-approved fentanyl patch, AVERSA(TM) Fentanyl integrates Nutriband's proprietary abuse-deterrent technology. This partnership aims to deliver the world's first abuse-deterrent opioid patch, addressing a significant public health crisis. The AVERSA(TM) technology is not only a testament to Nutriband's innovation but also to the potential for significant impact on the opioid epidemic, offering a safer alternative for patients in need of pain management solutions.

The market potential for AVERSA(TM) Fentanyl is substantial, with peak annual U.S. sales projected between $80 million and $200 million. Furthermore, Nutriband has laid the groundwork for global expansion, with patent protection secured in 46 countries. This strategic positioning underscores the company's commitment to addressing opioid abuse on a worldwide scale.

For more information on Nutriband Inc. and its pioneering work in abuse-deterrent technologies, visit https://www.nutriband.com. Additional updates and news regarding NTRB can be found at https://ibn.fm/NTRB.

The significance of the FDA's Type C Meeting cannot be overstated, as it not only validates the potential of AVERSA(TM) Fentanyl but also highlights the urgent need for innovative solutions in the fight against opioid abuse. Nutriband's progress with the AVERSA(TM) technology represents a beacon of hope for reducing the societal and health impacts of opioid misuse, setting a new standard for patient safety and care in pain management.